Fixed-Dose-Rate Gemcitabine: A Viable First-Line Treatment Option for Advanced Pancreatic and Biliary Tract Cancer

BACKGROUND. We have already reported on fixed-dose-rate gemcitabine (FDR-Gem) in advanced, inoperable pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC) in the context of a formal phase II study; building on that experience, we have now expanded the study to reach a cumulative ac...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Milella, Michele, Gelibter, Alain J., Pino, Maria Simona, Bossone, Giandominik, Marolla, Paolo, Sperduti, Isabella, Cognetti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2010
Assuntos:
Online Only
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227937/
https://ncbi.nlm.nih.gov/pubmed/20189980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2008-0135
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares